Our API product, Clarithromycin received the on-site audit from MFDS on October 19 to 21, 2016. This audit was the second one since the initial audit on April 11 to 13, 2011. Inspectors from MFDS performed strict system audit for clarithromycin production, testing, storage and file system. Eventually, 2 observations were made from the audit. After the analysis of the observations and risk assessment, the company made the corresponding corrective measures and written report of CAPA was submitted to MFDS.

The company has received a written certificate issued by MFDS for the on-site audit of Clarithromycin. Passing the audit not only recognizes the company's quality management system, but also increases the confidence of employees of the company. However, the result of the audit is not our only goal, our ultimate goal is continuously improving and optimizing the company's quality system. Encouraged by MFDS audit, the company will continue to maintain the strict requirements for our quality management system. In the meanwhile, we will keep the innovation and development and keep up with the advanced management technology in order to achieve the industry leading level.